Komiya T, Takase-Minegishi K, Sakurai N, et al. - Consecutive RA patients (n = 288) who received the same biological disease-modifying antirheumatic drugs (bDMARDs) with low disease activity or remission for at least 6 months were included to ascertain features of RA patients in Japan who got the same bDMARDs for at least 6 months and to recognize factors correlated with prosperous down-titration of bDMARDs dependent on shared decision-making. Sixty-six of 84 down-titration-treated patients proceeded to reveal low disease activity or remission, whereas 18 relapsed 18.9 ± 24.4 months following bDMARD down-titration was started. Univariate predictor analysis exhibited that no history of bDMARD treatment and low initial Disease Activity Assessment of 28 joint scores were the probable factors of down-titration. Other clinical features had no important association with prosperous down-titration. Thus, bDMARD-naïve patients and those with low initial disease activity are more inclined to agree to strive down-titration. Nonetheless, the timing and manner of down-titration should be made in shared decision-making among patients and rheumatologists.